NGS Sales Specialist - MidWest
Twist BioscienceSalary not specified
- Full Time
- Junior (1 to 2 years)
About Twist Bioscience
Twist Bioscience specializes in creating synthetic DNA for applications in biotechnology, pharmaceuticals, and research. Their proprietary platform allows for the quick and accurate production of DNA sequences, providing clients with products like genes, oligo pools, and variant libraries. The company stands out by offering high-quality DNA at competitive prices, making them a valuable partner for academic institutions and pharmaceutical companies. Twist Bioscience aims to support advancements in personalized medicine and biotechnology through their innovative DNA synthesis solutions.
South San Francisco, CaliforniaHeadquarters
2013Year Founded
$236.5MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
1,001-5,000Employees
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Disability Insurance
Life Insurance
401(k) Retirement Plan
Risks
Increased competition from Ginkgo Bioworks may impact Twist's market share.
Dependency on AI technologies could pose integration and operational challenges.
New CIO appointment may lead to transitional challenges in IT strategy and operations.
Differentiation
Twist Bioscience uses a unique silicon-based DNA synthesis platform for precision and scale.
They offer high-quality DNA sequences at competitive prices, attracting diverse clients.
Their proprietary platform provides instant feedback on DNA sequence synthesis feasibility.
Upsides
Growing demand for synthetic DNA in personalized medicine boosts Twist's market potential.
Collaboration with Absci leverages AI to accelerate antibody discovery and drug development.
Synthetic biology market projected to grow at 28.8% CAGR, benefiting Twist's growth.
Funding
Total raised$236.47 M
Latest valuation$372.40 M
StageIPO
POST IPO EQUITY
1/31/2022$250
IPO
9/30/2018$70
$372.40 MLATE VC
3/31/2018$50
$250.00 MSERIES E
5/31/2017$27
$135.00 MDEBT
8/31/2014$10
SERIES B
4/30/2014$26
$130.00 MSERIES A
1/31/2014$9
$45.50 M